细胞角蛋白19片段、组织多肽抗原和鳞状细胞癌抗原在预测宫颈癌宫颈外病变及预后中的价值。

Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.

作者信息

Gaarenstroom K N, Bonfrer J M, Korse C M, Kenter G G, Kenemans P

机构信息

Department of Gynecology, Leiden University Medical Center, The Netherlands.

出版信息

Anticancer Res. 1997 Jul-Aug;17(4B):2955-8.

PMID:9329574

Abstract

BACKGROUND

The value of serum Cyfra 21-1 level was compared with tissue polypeptide antigen (TPA), and squamous cell carcinoma antigen (SCC-Ag) in squamous cell cervical cancer.

MATERIALS AND METHODS

Pre- and post-treatment serum levels of patients were compared with lymph node status, parametrial involvement, and prognostic data.

RESULTS

Pretreatment serum levels of each marker were significantly related to tumor stage, tumor size and the presence of either lymph node metastases or parametrial involvement. The clinical performance of each marker in predicting extracervical disease at initial diagnosis appeared to be similar. None of these tests achieved the conditions of a perfect test. Pretreatment serum levels of each marker showed prognostic value in the univariate analysis. The clinical performance of post-treatment SCC-Ag levels in predicting complete remission versus the presence of tumor during follow-up was better than Cyfra 21-1 or TPA.

CONCLUSION

SCC-Ag appears to be more useful than Cyfra 21-1 for monitoring patients with cervical cancer.

摘要

背景

在宫颈鳞状细胞癌中，对血清细胞角蛋白19片段（Cyfra 21-1）水平与组织多肽抗原（TPA）和鳞状细胞癌抗原（SCC-Ag）的价值进行了比较。

材料与方法

将患者治疗前和治疗后的血清水平与淋巴结状态、宫旁组织受累情况及预后数据进行比较。

结果

每种标志物的治疗前血清水平与肿瘤分期、肿瘤大小以及是否存在淋巴结转移或宫旁组织受累显著相关。在初始诊断时，每种标志物预测宫颈外疾病的临床性能似乎相似。这些检查均未达到完美检查的条件。在单因素分析中，每种标志物的治疗前血清水平显示出预后价值。在随访期间，治疗后SCC-Ag水平预测完全缓解与肿瘤存在情况的临床性能优于Cyfra 21-1或TPA。